Our Resources

Most of our prospective clients understand that virtual represents a new frontier in clinical research but often ask how to implement virtual solutions into their studies. Is this you? Maybe you already have a written protocol and want to gauge the possibility of a virtual transition, or perhaps you want first to determine the most effective trial design. Because these are scenarios we see so frequently, we thought we could offer a playbook to help you imagine your studies in a virtual way. Here are four big-ticket items that will impact how your study proceeds.

For patients with rare, incurable, or life-threatening diseases, clinical trials can offer new hope. Cancer patients, specifically, are often highly motivated to participate in research, particularly when they have an advanced or treatment-resistant form of cancer. Find out how decentralized clinical trials reach patients in the comfort of their homes.

While there's broad agreement on the gap between white and non-white participation in clinical trial enrollment, the number of non-white patients enrolled in clinical trials for general population studies is still quite low.‍ But why?

Digital instruments such as sensors and wearables are transforming the industry’s definition of accuracy in three measures: volume, practicality, and precision.

ObvioHealth and Renovia conducted a groundbreaking study on the efficacy of an at-home medical device for the treatment of stress and mixed urinary incontinence. Read more below to understand how we delivered a successful, fully virtual clinical trial in the midst of the pandemic.

Expectations for the time it takes to complete a vaccine clinical trial have been radically raised by the mRNA vaccines’ successes.

Decentralized trials (DCTs) expand older adults’ access to trials, allowing them to participate at higher rates.

ObvioHealth successfully conducted a clinical trial for RedHill Biopharma to test the safety and efficacy of an oral medication for the treatment of COVID-19 symptoms. We designed this decentralized study to be conducted where the majority of patients recover from illness—in their homes. When the trial was launched in 2021, its unique combination of home health visits, electronic patient-reported outcomes (ePRO), and remote monitoring devices was pioneering—COVID-19 studies were typically conducted inside hospitals.